Premium
Diet medications and valvular hearl disease: the current evidence
Author(s) -
Barasch Andrei,
Safford Monika M.
Publication year - 2002
Publication title -
special care in dentistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.328
H-Index - 41
eISSN - 1754-4505
pISSN - 0275-1879
DOI - 10.1111/j.1754-4505.2002.tb01172.x
Subject(s) - dexfenfluramine , medicine , phentermine , fenfluramine , valvular heart disease , interim , disease , anorectic , intensive care medicine , obesity , food intake , weight loss , receptor , archaeology , serotonin , history
Since 1997, the appetite suppressant drugs fenfluramine‐phentermine (fen‐phen) and dexfenfluramine have been associated with the development of valvular heart disease. As a result, the drugs have been withdrawn from the market and interim recommendations for evaluation and treatment of exposed patients were issued. However, subsequent studies showed lower prevalence rates for valve abnormalities than were initially reported, and the possibility of such drug‐induced lesions resolving has been raised. This article reviews relevant evidence and discusses concerns for the dental practitioner.